530 Old Whitfield Street
Guilford, CT 06437
Henri Lichenstein – President and CSO
AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat lymphangioleiomyomatosis (LAM) and major cancers. Working with proprietary technologies AI Therapeutics operates at the intersection of molecular and cell biology, genetics, instrumentation and automation. The in-house team and its collaborators are working to advance drugs that are specifically tailored to patient populations that will respond best.
CT Employees: 6
World Employees: 6